GLP‑1, GLP‑1/GIP, and GLP3R: The Alphabet, in Plain English

GLP‑1 is a hormone your body already makes after you eat. It slows stomach emptying, signals fullness to the brain, and helps regulate blood sugar. Medications in this family imitate that signal.

Semaglutide activates the GLP‑1 receptor — one pathway. Tirzepatide activates GLP‑1 and GIP — two pathways that work together on appetite and metabolism. Retatrutide (which Vitality calls GLP3R) is the newest direction in this research: a triple agonist that adds the glucagon receptor. It is investigational and not FDA-approved, which is exactly the kind of detail a provider should walk you through before it is ever part of a conversation about your care.

None of these medications are magic, and none of them are right for everyone. Side effects, health history, other medications, cost, and follow-up all matter. Compounded versions are not FDA-approved, and product sourcing is worth asking hard questions about — including whether each lot is tested.

What separates a good experience from a bad one is rarely the molecule. It is whether someone reviewed your history first, set honest expectations, and stayed with you through the follow-up. That is the conversation a free Discovery Call starts.

This article is general education only and is not medical advice, diagnosis, dosing instruction, or treatment. Individual care decisions require provider review.